Phase I Dose‐Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors

LESSONS LEARNED. Ramucirumab was well tolerated in Chinese patients with advanced solid tumors, and adverse events were manageable in this study. Pharmacokinetics characteristics in Chinese patients were similar to those in other populations. Immunogenicity was not detected. No efficacy conclusion c...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Junning, Ji, Dongmei, Chen, Zhiyu, Shen, Weina, Wang, Jin, Li, Baoyue, Chi, Haidong, Long, Amanda, Gao, Ling, Li, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469595/
https://www.ncbi.nlm.nih.gov/pubmed/28465370
http://dx.doi.org/10.1634/theoncologist.2017-0137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469595/
https://www.ncbi.nlm.nih.gov/pubmed/28465370
http://dx.doi.org/10.1634/theoncologist.2017-0137

Ejemplares similares